See attached CASTLE IRB NEWSLETTER dated March 2022 Volume 2. This Release relates to our very own Dr .Daniel N. Rastien, PFD FDA IRB Program Coordinator, of whom we are so very proud. In addition to being retained by the PFD team to coordinate the Institutional Review Board Sponsored by Advarra for the PFD/iOrthopedics INC new orthopedic Resilient Arthroplasty Device (RAD) referred to as ‘iKnee’, Dr. Rastein, MD, MPH is also the Founder & CEO of CassdermaRX, one of only four portfolio projects selected as meeting the exacting standards of PFD Capital Partners for the PFD Management Opportunity Fund 3001, LLC.